EDTUTC-4 New YorkLog in Sign up

RHHBY
ROCHE HOLDING LTD S/ADR
stockOTCADR

EODOct 2, 2026

52.25USD-0.191%(-0.10)640,792

RHHBY News

Day breaks

07:32 AM EDTMedicare drug pricing model to affect only four firms after Trump’s MFN policy ·

Seeking Alpha

02:47 AM EDTRoche's Vabysmo Shows Real-World Effectiveness Across Retinal Diseases ·

RTTNews

02:00 AM EDTRoche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions ·

GlobeNewswire Inc.

01:00 AM EDTRoche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine ·

GlobeNewswire Inc.

02:22 PM EDTRoche multiple sclerosis pill gets FDA priority review ·

Seeking Alpha

10:24 AM EDTCould This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market? ·

The Motley Fool

02:33 AM EDTRoche launches newborn screening test for three severe genetic conditions ·

Seeking Alpha

01:00 AM EDTRoche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis ·

GlobeNewswire Inc.

08:43 PM EDTRoche Holding AG (RHHBY) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas Transcript ·

Seeking Alpha

12:54 PM EDTRoche Plans Autonomous AI Labs To Accelerate Drug Discovery ·

RTTNews

02:38 PM EDTGenentech's Gazyva gains indication for idiopathic nephrotic syndrome ·

Seeking Alpha

02:13 PM EDTBeyond GLP-1 injectables, who wins the next phase for obesity drugs? ·

Seeking Alpha

03:36 PM EDTFDA commissioner nominee Overton rebuffs questions about Trump medical claims ·

Seeking Alpha

09:28 AM EDTRoche, Atavistik Bio partner on allosteric drug discovery ·

Seeking Alpha

08:51 AM EDTRoche, Ionis succeed in late-stage trial for kidney disease therapy ·

Seeking Alpha

01:15 AM EDTPositive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN) ·

GlobeNewswire Inc.

03:15 PM EDTIs Regeneron Stock a Bargain Below $800? ·

The Motley Fool

06:52 AM EDTRoche GLP-1 delivers 16% weight loss in mid-stage trial ·

Seeking Alpha

01:00 AM EDT[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity ·

GlobeNewswire Inc.

01:04 PM EDTRoche nabs European approval of Susvimo for neovascular AMD ·

Seeking Alpha